Diffuse panbronchiolitis in East Asia

  title={Diffuse panbronchiolitis in East Asia},
  author={Arata Azuma and Shoji Kudoh},
Abstract:  Diffuse panbronchiolitis is characterized by chronic sinobronchial infection and diffuse bilateral centrilobular lesions consisting of peribronchial infiltration of inflammatory cells. At present, it is known that diffuse panbronchiolitis is relatively restricted to East Asia. This uneven distribution is suspected to be highly associated with genetic predisposition located between human leucocyte antigen‐A and ‐B loci. Low‐dose, long‐term macrolide therapy for the disease was… 

Diffuse panbronchiolitis cases in India: An update

The prognosis of DPB significantly improved after introduction of long‐term, low dose of erythromycin therapy in 1985, giving it a recognition of distinct clinical entity.

Diffuse panbronchiolitis-The response and recurrence after erythromycin therapy.

Diffuse Panbronchiolitis: Long-Term Low-Dose Macrolide Therapy

The history of the development of long-term low-dose macrolide therapy for DPB, and the mechanisms by which this therapy exerts its clinical benefits are introduced.

Clinical profiles of 12 Chinese patients with diffuse panbronchiolitis.

More DPB cases need to be analyzed from Chinese population due to different presentations compared to Japanese population and this experience should help other clinicians in the investigation and management of DPB in non-Japanese patients.

Diffuse panbronchiolitis in an adolescent female

A 16-year-old girl with DPB who presented with chronic cough and sputum is described, which is uncommon in children and indicates a genetic predisposition unique to Asians.

Deterioration of Asthma in a Patient With Diffuse Panbronchiolitis (DPB) After Macrolide Therapy

The authors’ patient was diagnosed with DPB and asthma, and macrolide therapy led to the disappearance of the radiologic abnormalities indicating centrilobular nodular lesions, but the respiratory symptoms and pulmonary function worsened.

Macrolides for diffuse panbronchiolitis.

There is little evidence for macrolides in the treatment of DPB and it may be reasonable to use low-dose macrolide soon after diagnosis is made and to continue this treatment for at least six months, according to current guidelines.

Diffuse panbronchiolitis

In its advanced stages, diffuse panbronchiolitis is characterized by extensive bronchiectasis and carries a poor prognosis de spite treatment with erythromycin, which has been shown to improve pulmonary function, clinical symptoms and survival rate in these patients.

Diffuse panbronchiolitis: not just an Asian disease: Australian case series and review of the literature

It is proposed that this disease also occurs in Caucasians and the incidence in this population is greater than currently recognised and high resolution computed tomography and response to macrolide therapy should be relied upon to make this diagnosis without verification by lung biopsy.



Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent.

The immigration of Asians and sporadic case reports involving non-Asians make recognition of this disease entity important, as the implications for therapy are different than that of other small airway diseases.

Diffuse panbronchiolitis. A disease of the transitional zone of the lung.

Diffuse panbronchiolitis belongs to a distinctly different category from these diseases, and should be distinguished from them, because it may often show rapid progression with fatal outcome.

Clinical profiles of Chinese patients with diffuse panbronchiolitis

The only series of non-Japanese Mongoloid patients with well characterised DPB who had uncharacteristic investigation profiles are reported and should help other clinicians in the investigation and management of DPB in non- Japanese patients.

Diffuse panbronchiolitis, the first case reports in Thailand.

Diffuse panbronchiolitis should be suspected in patients who have clinical manifestations of chronic cough, productive sputum and shortness of breath and chronic treatment with low-dose erythromycin can improve the survival of patients.

Diffuse panbronchiolitis in an Asian immigrant.

The known efficacy of low dose erythromycin in DPB was again confirmed after failure of long term high dose corticosteroid therapy administered before an accurate diagnosis had been made.

Analysis of HLA antigens in patients with diffuse panbronchiolitis.

HLA analysis of patients with diffuse panbronchiolitis found that Bw54, or its related haplotype, exists only in Japanese, Chinese, and Korean populations, which suggests that one or some of the genes controlling the susceptibility and/or immune responsiveness of diffusePanbronChiolitis might be located near HLA loci.

The first report of diffuse panbronchiolitis in Korea: five case reports.

In three clinically and radiologically suspected cases, high resolution computed tomography showed the typical findings of DPB and other diseases such as pulmonary emphysema, bronchial asthma, chronic bronchitis and bronchiectasis could be ruled out.

Diffuse panbronchiolitis in Latin America.

The present case shows that DPB, although rare in Western countries, is not a disease restricted to Asia, and always should be considered in the differential diagnosis of nodular radiographic opacities associated with airflow limitation, especially in non-smokers with a history of chronic sinusitis.

A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.

The number of neutrophils in the peripheral blood was not affected by erythromycin, indicating that the drug was not toxic, and there was a significant correlation between the reduction of NCA and neutrophil percentage in pre- and post-eryhromycin treatment BALF.